Automatic Website Traffic RSS

Sarah Blagden, oncologist: ‘We should eventually have a vaccine that you get at age 40 that protects you from cancer’

The University of Oxford researcher is testing a revolutionary injection to prevent the appearance of lung cancer, the most common and deadly form of the disease ... read more

EXCLUSIVE: Virax Biolabs Launches Immune Profiling Solutions To Evaluate Adaptive Immunity In Post-Viral Syndromes

Unlock the potential of adaptive immunity with ImmuneSelect by Virax Biolabs. Investigate T-Cell driven immunity for post-viral syndromes like Long COVID. Explore peptide pools and recombinant ... read more

EpiVax gets grant for patent granted for T-cell epitope composition to suppress immune response

Discover how EpiVax's patented T-cell epitope composition can induce regulatory T-cells to suppress immune responses in subjects. Explore the potential therapeutic benefits now! read more

New trials show promise for immune checkpoint blockers in early-stage lung cancer

A dendritic cell (DC) vaccine targeting patient-specific neoantigens to patients with resected non-small cell lung cancer (NSCLC). read more

Astellas Pharma gets grant for antibodies for diagnosing cancer by detecting cldn6 expression

Discover how Astellas Pharma's patent for antibodies targeting CLDN6 revolutionizes cancer diagnosis and treatment. Learn about the specific amino acid sequences and potential applications in this ... read more

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

CureVac continues to advance its clinical development programs in prophylactic vaccines in collaboration with GSK. All currently tested candidates apply modified mRNA and are based on CureVac’s ... read more

Vaccines targeting chronic diseases show promise in combatting age-related conditions

Vaccines for age-related vascular diseases such as hypertension, abdominal aortic aneurysm (AAA), and atherosclerosis target molecules that regulate blood pressure, cholesterol, and blood vessel ... read more

CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript

Q4 2023 Earnings Call April 24, 2024 CureVac N.V. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to ... read more

Universal Vaccine Strategy Boosts Body’s RNAi Response to Viruses

Researchers say there is little chance of a virus mutating to avoid this vaccination strategy, which blocks viral ability to suppress host RNAi responses. read more

Maintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory Hurdles

Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani, and Andrew S. read more

Retinoblastoma Origins and Destinations

For permission requests, please contact NEJM Reprints at [email protected] We and others identified retinoblastoma features that suggested that the tumors originate in long- and medium-wavelength cone ... read more

CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Organizational redesign and rightsizing initiated across company to streamline structures, increase efficiency and reduce operating costs Together with GSK, ended Pandemic Preparedness Agreement (PPA) ... read more